No, you usually do not need a familial Alzheimer's genetic panel for a dementia diagnosis. This panel looks for rare disease-causing variants linked to inherited, often early-onset Alzheimer's disease. Clinicians ordinarily diagnose dementia using medical and family history, cognitive and daily-function assessments, a neurological examination, imaging, and blood or cerebrospinal-fluid tests. The Alzheimer's Association outlines these diagnostic tools, with genetic panels reserved for selected situations.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does the standard diagnostic process involve?
- When might a familial panel be appropriate?
- What can a panel find?
- Who should be tested first?
- APOE is a risk test, not a diagnostic panel
What does the standard diagnostic process involve?
A dementia evaluation asks two related questions: Has thinking declined enough to interfere with daily life, and what condition is causing that decline? Genetic testing cannot answer either question by itself. Clinicians assess memory and other thinking skills, changes in everyday function, symptoms, medication use, and medical history.
They may use brain imaging and laboratory tests to investigate Alzheimer's disease and other possible causes. This distinction matters because a person can receive an Alzheimer's diagnosis without finding an inherited variant. Likewise, a genetic result alone does not describe the person's current cognitive ability or level of independence.
When might a familial panel be appropriate?
A specialist may consider testing when dementia begins unusually early or when the family pattern resembles autosomal-dominant inheritance. That pattern usually involves affected relatives across at least two generations, rather than one older relative with dementia.
The Alzheimer's Association diagnostic guideline recommends shared decision-making with the patient and family. Before ordering a panel, a specialist may examine: A referral to a memory-disorders specialist or genetics professional is a practical next step when these features are present. Bring a family history covering parents, siblings, children, grandparents, aunts, and uncles when possible.
- The affected person's age when symptoms began
- Which relatives developed dementia and at what ages
- Whether cases appear in successive generations
- Whether living affected relatives are available for testing
- How a result could affect relatives and future decisions
What can a panel find?
The principal genes associated with deterministic familial Alzheimer's disease are APP, PSEN1, and PSEN2. "Deterministic" means that a disease-causing variant gives a person a very strong probability of developing the disease, rather than merely increasing susceptibility. These variants are rare. According to the National Institute on Aging's genetics fact sheet, they explain about 10% to 15% of early-onset cases, and fewer than 10% of all Alzheimer's cases begin before age 65.
A child whose parent carries a disease-causing variant in one of these genes has a 50% chance of inheriting it. This is why one result may carry consequences for siblings, adult children, and other blood relatives. A panel may also return a variant of uncertain significance. Such a finding means the laboratory detected a genetic change but cannot establish that it causes disease. It should not be treated as a confirmed explanation for dementia.
Who should be tested first?
Testing should usually begin with a relative who has dementia. Finding a pathogenic APP, PSEN1, or PSEN2 variant in an affected person establishes a specific target for other relatives. Predictive testing in an unaffected adult becomes most informative after that family variant has been identified. Without it, a negative result may not explain the family history or show that the person is free of inherited risk.
Genetic counseling should take place before and after testing. A counselor can explain possible results, whether the test is likely to answer the family's question, and how information could affect relatives. Counseling also creates space to consider psychological, social, and financial consequences. Family members may make different choices about whether they want predictive information, even when they share the same potential risk.
APOE is a risk test, not a diagnostic panel
APOE testing serves a different purpose from testing APP, PSEN1, and PSEN2. The APOE ε4 form raises susceptibility to Alzheimer's, but some carriers never develop the disease. Its absence does not rule Alzheimer's out. Consumer APOE reports therefore cannot diagnose dementia or calculate a person's complete Alzheimer's risk.
Interpretation may be limited by ancestry, environmental influences, untested variants, and differences among company panels. APOE genotyping can have a separate role after diagnosis when treatment is being considered. The FDA prescribing information for donanemab recommends testing before treatment because people with two APOE ε4 copies face greater risk of amyloid-related imaging abnormalities, or ARIA. Patients may still receive treatment without genotyping after counseling about that risk.
